The study is based on the hypothesis that increased nuchal translucency may be associated with a materno fetal infection and that the pathogen responsible for this infection could be identify with metatranscriptomic next-generation sequencing in the trophoblast tissue.
Nuchal translucency \> 3.5 mm in the first trimester of pregnancy is due to fluid accumulation in the subcutaneous tissue in the nuchal area. This is seen in around 1% of all pregnancies. Increased nuchal translucency is explained by a chromosomic abnormality (mainly Down syndrome) in 30 to 40% of cases. Therefore, the state of the art is to perform an array CGH on chorionic villi sampling. Cases of nuchal translucency that are not explained by a chromosomic abnormality may be associated: with fetal defect (heart, congenital diaphragmatic hernia) in 10% of cases, with genetic disease in 4% of cases or with miscarriage or fetal death of unknown etiology in 18% of cases. The etiology of increased nuchal translucency remains unknown in more than 50% of the cases. It could be linked to inflammation or reflect an infection but this latter association has been rarely studied. This association was suggested in a study reporting serology of CMV, toxoplasmosis or B19 parvovirus primary infections in pregnant women carrying a fetus with increased nuchal translucency. In those rare cases, the microorganism was not searched directly in the trophoblast tissue. In the investigators' center, the investigators describe in a context of maternal primary infection, one case of increased nuchal translucency with a positive CMV PCR in the trophoblast tissue collected at 12 weeks. Other pathogens yet not identified might be associated with increased nuchal translucency. Metatranscriptomic next generation sequencing (mNGS) allows to search for any pathogens without a priori. It is therefore a powerful technic to study this potential association between increased nuchal translucency and infection.
Study Type
OBSERVATIONAL
Enrollment
110
Analysis with metatranscriptomic next generation sequencing of trophoblast obtained by chorionic villi sampling
If a microorganism is detected by metatranscriptomic NGS, specific diagnosis (PCR and serology) will be done in maternal and neonatal samples (blood, urine, saliva)
Hopital Necker - Enfants malades
Paris, France
RECRUITINGmicroorganisms (viruses, bacteria, or parasites) in trophoblast samples
Identification by metatranscriptomic NGS, from women carrying a fetus with nuchal translucency (group 1) and in controls (group 2 and 3)
Time frame: At inclusion, 11-14 weeks of pregnancy
Miscarriage
Comparison in group 1 of the proportion of miscarriageaccording to the presence or not of a microorganism in the trophoblast.
Time frame: at termination of pregnancy (assessed up to 7 months)
intrauterine death
Comparison in group 1 of the proportion of intrauterine death according to the presence or not of a microorganism in the trophoblast.
Time frame: at termination of pregnancy (assessed up to 7 months)
fetal abnormalities
Comparison in group 1 of the proportion of fetal abnormalities, according to the presence or not of a microorganism in the trophoblast.
Time frame: at delivery
Gestational age
Comparison in group 1 of gestational age at birth, according to the presence or not of a microorganism in the trophoblast.
Time frame: at delivery
birth weight
Comparison in group 1 of birth weight, according to the presence or not of a microorganism in the trophoblast.
Time frame: at delivery
Detection of the microorganism identified by metatranscriptomic NGS by conventional diagnostic method in maternal samples
Amplification by real time PCR of the microorganism identified by metatranscriptomic NGS in maternal blood, urine, saliva and amniotic fluid if available
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.
Time frame: at inclusion
Detection of the microorganism identified by metatranscriptomic NGS by conventional diagnostic method in maternal samples
specific serology to identify a maternal primary infection with the microorganism detected by metatranscriptomic NGS
Time frame: at inclusion
Detection of the microorganism identified by metatranscriptomic NGS by conventional diagnostic method in neonatal samples
Amplification by real time PCR of the microorganism identified by metatranscriptomic NGS in neonatal blood, urine, saliva
Time frame: 3 days after birth
Detection of the microorganism identified by metatranscriptomic NGS by conventional diagnostic method in neonatal samples
specific serology to identify a maternal primary infection with the microorganism detected by metatranscriptomic NGS
Time frame: 3 days after birth